---
title: "Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289614824.md"
description: "Silence Therapeutics (SLN) shares rose 2.84% following positive Phase 1 SANRECO data for divesiran in polycythemia vera, showing sustained benefits and improved quality of life. Analysts from William Blair highlighted divesiran's favorable dosing schedule compared to competitor rusfertide, reiterating an Outperform rating. The company expects Phase 2 topline results in August 2026."
datetime: "2026-06-12T14:47:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289614824.md)
  - [en](https://longbridge.com/en/news/289614824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289614824.md)
---

# Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

**Silence Therapeutics Plc** (NASDAQ:SLN) shares are up during Friday’s session. On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran.

## SLN Stock Catalyst: SANRECO Phase 1 Follow-Up Data

Recent analyses from the Phase 1 SANRECO study show potential improvements in symptoms and quality of life for patients with polycythemia vera (PV).

Additional analyses also showed reductions in phlebotomy use persisted well beyond the final dose.

The ongoing Phase 2 SANRECO study is on track to deliver topline results in August 2026, further supporting the stock’s upward movement.

**Read Also: These 10 Stocks Are Getting Crushed By Short Sellers Right Now**

## William Blair Highlights Divesiran’s Competitive Position

William Blair said Thursday that additional analyses from the Phase 1 SANRECO trial reinforce positive momentum for Silence Therapeutics and divesiran in polycythemia vera (PV), with topline Phase 2 data expected in the third quarter.

**Protagonist Therapeutics Inc.** (NASDAQ:PTGX)/**Takeda's** (NYSE:TAK) rusfertide is positioned for a potential first-to-market advantage in PV, with FDA approval expected in the third quarter of 2026.

Analyst Myles Minter believes divesiran offers comparable efficacy and remains best-in-class among TMPRSS6 silencers. He highlighted its favorable dosing schedule (every 6–12 weeks versus weekly rusfertide injections) and safety profile.

## Cardiovascular Pipeline Offers Additional Upside

The analyst also pointed to Silence's cardiovascular disease pipeline, which targets well-validated pathways, as providing multiple value-creation opportunities for the company's mRNAi GOLD platform.

William Blair reiterated its Outperform rating.

**SLN Stock Price Activity:** Silence Therapeutics shares were up 2.84% at $6.87 at the time of publication on Friday, according to Benzinga Pro data.

_Image via Shutterstock/ Yomal2233_

**Read Also: Trump Pushes To Expunge His Impeachments As Experts Call The Plan 'Absurd:' Report**

### Related Stocks

- [SLN.US](https://longbridge.com/en/quote/SLN.US.md)
- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [09:50 ETBlood Cancer United Honors National Visionaries of the Year Winners for Extraordinary Impact](https://longbridge.com/en/news/293629548.md)
- [09:35 ETECRI Names Cottage Health Winner of 2026 Health Technology Excellence Award](https://longbridge.com/en/news/294216987.md)
- [James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition](https://longbridge.com/en/news/294085325.md)
- [Disc Medicine publishes corporate presentation on hematology pipeline targeting heme, iron pathways](https://longbridge.com/en/news/294368343.md)
- [GLP-1 drugs could reduce long-term sick leave: Study](https://longbridge.com/en/news/293847884.md)